News

FDA asks ARIAD to suspend marketing and sales of Iclusig (ponatinib)

The U.S. Food and Drug Administration (FDA) has asked ARIAD Pharmaceuticals, the manufacturer of Iclusig (ponatinib) to suspend marketing and sales of ponatinib because of the risk of life-threatening blood clots and severe narrowing of [...]

By |2019-09-20T11:38:58-04:00November 1st, 2013|Drug Treatment, News|

Stivarga Approved for Canadian GIST Patients

Health Canada has expanded approval for the use of Stivarga to fight Gastrointestinal Stromal Tumours (GIST), according to an article from CNW. Bayer announced that Stivarga will now be available for treatment of adult patients with [...]

By |2019-09-20T11:39:34-04:00October 18th, 2013|Drug Treatment, News, Stivarga|

ARIAD Ponatinib Trial Pauses Accepting New Patients

ARIAD has announced that their ponatinib (Iclusig) trial, which some GIST patients are participating in, has paused new enrollment based on consultations with the FDA regarding patients who experienced particular vascular events. Subject to agreement with [...]

By |2019-09-20T11:44:57-04:00October 10th, 2013|Clinical Trials, News|

Access to Information, Health Equity and Knowledge in Cancer Care

Here is a recently published article from Alianza GIST Brazil representative Valeria Hartt about access to information, health equity and knowledge in cancer care in Brazil. Valeria described her article below: In order to add contributions [...]

By |2019-09-20T11:47:03-04:00October 8th, 2013|News|
Go to Top